Association of Pretreatment Neutrophil-to-Eosinophil Ratio with Clinical Outcomes in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Treated with Nivolumab.
Shinsuke SuzukiTomoe AbeTentaro EndoHaruka KayaTakuro KitabayashiYohei KawasakiTakechiyo YamadaPublished in: Cancer management and research (2022)
A pretreatment feature of low NER (NER <32) may predict better clinical outcomes in patients with R/M HNSCC treated with nivolumab.